ClinicalTrials.gg
RecruitingNCT07691307Updated Jul 8, 2026

A Study to Evaluate the Safety and Performance of TruGamma System for Tricuspid Replacement

An interventional study of TruGamma System and Optimal medical therapy (OMT) in Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency and Tricuspid Valve Disease, sponsored by Jiangsu Trulive Medical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Jiangsu Trulive Medical Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Mar 2026, registered Jun 2026).
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Tricuspid Valve Insufficiency with a site in China — 19 open to participants now, 21 under way, none of them phase 3. Tricuspid Valve Insufficiency · China.

Planned enrollment
5th of 16
180 · median 129
Started
2026
with 4 others
No phase
15 of 28
9 open now
Primary completion
2028-08
later than 15 of 20 live
Registered
25th of 28
by date

Among the 28 studies in Tricuspid Valve Insufficiency with a site in China, this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2026, is one of 15 with no phase, reaches primary completion later than 15 of the 20 other live ones, and was the 25th registered.

Tricuspid Valve Insufficiency

229 studies on the registry are indexed under Tricuspid Valve Insufficiency; 111 are open to participants now.

Browse Tricuspid Valve Insufficiency studies →

Open to participants now

19 of the 28 studies in Tricuspid Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 81 Tricuspid Valve Insufficiency studies recruiting now, 67 (83%) set no upper age limit and none (0%) stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Tricuspid Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

Pivotal trial to evaluate the safety and effectiveness of the TruGamma tricuspid valve replacement system

Read the detailed description

The study is a prospective, multi-center, randomized controlled pivotal clinical trial to evaluate the safety and effectiveness of the TruGamma System with optimal medical therapy (OMT) compared to OMT alone in the treatment of patients with at least severe tricuspid regurgitation. Subjects will be followed at discharge, 30 days, 3 months, 6 months and annually through 5 years.

03

Conditions studied

  • Tricuspid Valve Regurgitation
  • Tricuspid Valve Insufficiency
  • Tricuspid Valve Disease

Keywords

  • tricuspid valve replacement
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥65 years old.
  2. The subject must be assessed by the local heart team as a high-risk patient ineligible for surgery and has been stabilized on optimal medical therapy (OMT)(The OMT is evaluated by the local heart team and comprises medications including diuretics with a treatment duration of no less than 30 days; no medication was newly initiated or discontinued within the preceding 2 weeks before treatment, any dose reduction did not exceed 50% of the original dose, and any dose escalation did not exceed 100% of the original dose.).
  3. Despite OMT per the local heart team, patient has signs of TR or symptoms fromTR,and TR graded as at least severe on a TTE(assessedby the 5-grade classification).
  4. (NYHA) Class III-IV.
  5. The local heart team determines that the subject's anatomy is appropriate for transcatheter tricuspid valve replacement.
  6. Subject is willing and able to comply with all study evaluations and provideswritten .

Exclusion criteria

Exclusion Criteria:

  1. Transesophageal echocardiography (TEE) is or cannot be completed.
  2. Pulmonary arterial systolic pressure (PASP) >60 mmHg by Dopplerechocardiogram (unless right heart catheterization [RHC] demonstrates PASP ≤60 mmHg).
  3. (LVEF) ≤ 25%.
  4. Severe aortic, mitral, and/or pulmonic valve stenosis and/or regurgitation requiring surgical intervention.
  5. Previous tricuspid surgery or intervention.
  6. Patients with congenital Ebstein's anomaly or hypoplastic right ventricle.
  7. Patients with right ventricular outflow tract obstruction,or hemodynamically significant pericardial effusion,or significant intracardiac mass, thrombus, or vegetation.
  8. Active endocarditis within the last 90 days or infection requiring antibiotictherapy within the last 14 days.
  9. Hemodynamic instability with cardiogenic shock or severe hemodynamic compromise, defined as systolic blood pressure (SBP) \<90 mmHg with or without vasoactive or afterload-reducing agents, cardiogenic shock , or the need for an intra-aortic balloon pump (IABP), or other mechanical circulatory support (MCS) devices.
  10. Patients with respiratory failure who are deemed to be unsuitable candidates for general anesthesia.
  11. Severe renal insufficiency with estimated (eGFR) \<30mL/min/1.73m2,or requiring chronic renal replacement therapy.
  12. Patients with hepatic insufficiency, or cirrhosis with Meld-3.0 score >17.
  13. , untreated coronary artery disease requiringrevascularization, recent acute coronary syndrome within the last 30 days.
  14. Any major cardiac, coronary, or cervical vascular surgery within the last 30 days.
  15. Pacemaker or ICD leads that may interfere with implantation of the tricuspid valve system.
  16. Pulmonary embolism in the last 6 months (180 days).
  17. Ischemic or hemorrhagic stroke within the last 90 days .
  18. Active peptic ulcer disease or upper gastrointestinal bleeding within the last 90 days.
  19. Chronic anemia with transfusion dependency or \<90g/L not corrected by transfusion.
  20. Thrombocytopenia ( count\<75,000/mm3) or thrombocytosis (plateletcount >750,000/mm2).
  21. Unable to perform the 6-minute walk test (6MWT).
  22. reaction or known allergy to the raw materials of the device ,or other allergy cannot be adequately managed with medication.
  23. Severe Alzheimer's disease.
  24. Known contraindication, allergy, or hypersensitivity to BOTH dual antiplatelet therapy AND anticoagulant therapy. A contraindication to either DAPT or anticoagulant therapy alone does not constitute an exclusion criterion.
  25. Active or ≤1 year, in the opinion of the investigator.
  26. Severe uncontrolled hypertension.
  27. Pregnancy, breastfeeding, or a positive pregnancy test at screening, or intention to become pregnant during the study period. (Women with documented history of menopause are exempt.)
  28. Concurrent participation in another investigational drug or device clinical trial in which the primary endpoint has not yet been reached.
  29. In the opinion of the investigator, the subject is unlikely to comply with study procedures or to complete the study as required.
  30. Any other condition or circumstance that, in the judgment of the investigator, would make the subject inappropriate for study enrollment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    TruGamma System & OMT

    Transcatheter tricuspid valve replacement with the TruGamma System in conjunction with optimal medical therapy (OMT) in patients with tricuspid regurgitation.

    Device: TruGamma System

  • Active comparator
    Optimal Medical Therapy (OMT)

    Optimal medical therapy (OMT) alone in patients with tricuspid regurgitation

    Drug: Optimal medical therapy (OMT)

Interventions

  • DeviceTruGamma System

    Transcatheter tricuspid valve replacement with the TruGamma System in conjunction with OMT

    Also known as: Transcatheter tricuspid valve replacement

  • DrugOptimal medical therapy (OMT)

    Optimal Medical Therapy

06

What researchers measure

Primary outcomes

  1. Hierarchical composite endpoint including: Kansas City Cardiomyopathy Questionnaire (KCCQ) improvement, New York Heart Association (NYHA) functional class improvement, and 6-minute walk test distance improvement

    Comparison of number of wins with composite endpoint event improvement between experimental and active comparator arm.KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better health status.NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

    Time frame: 12months

  2. Tricuspid Regurgitation (TR) severity

    Comparison of percentage of patients with tricuspid regurgitation of 2+ or less between experimental and active comparator arm.TR severity will be assessed using the 5-grade scale with the addition of "none/trace" to represent the lack of TR (scale: none/trace, mild, moderate, severe, massive, torrential). Lower grades of TR are better.

    Time frame: 12months

  3. Rate of Major Adverse Events (MAE)

    Rate of Major Adverse Events (MAE) in experimental arm(TruGamma System in conjunction with OMT)

    Time frame: 30 days

Secondary outcomes

  1. Procedural success rate

    Procedural success rate in experimental arm.Criteria for procedural success (all of the following items shall be satisfied): No intraprocedural death or stroke;The device is successfully delivered via the jugular vein into the right atrium, across the tricuspid valve and into the right ventricle, followed by deployment of the prosthetic valve and removal of the delivery system;The implanted valve is positioned at an appropriate anatomical site;No moderate or greater transvalvular regurgitation, no moderate or greater paravalvular leakage, and no tricuspid stenosis of the implanted valve;No device-related forward flow obstruction or pulmonary embolism; No device- or access site-related complications requiring urgent reoperation or other reintervention within 24 hours after the procedure.

    Time frame: Immediately after procedure

  2. Clinical success rate

    Clinical success rate in experimental arm.Criteria for clinical success (all of the following shall be met): No procedural death or stroke; The implanted valve is positioned at an appropriate anatomical site, with no moderate or greater transvalvular regurgitation, no moderate or greater paravalvular leakage and no tricuspid stenosis. There are no device- or access site-related complications requiring reoperation or other reintervention; No major adverse events (MAE) related to the device or procedure.

    Time frame: 30 days

  3. System performance evaluation

    Intraoperative performance evaluation of the transcatheter tricuspid valve system, including overall device performance, ease of use of the delivery system, compatibility of the delivery system with the loaded prosthetic valve, priming performance, visualization, pushability and trackability of the delivery system, compatibility among all components of the delivery system, hemostatic performance of the delivery system, positioning function for the prosthetic valve, leaflet capture and control function, interaction between the system and adjacent anatomical structures, stability and operability during valve deployment, and retraction performance. Thrombosis or embolism shall also be assessed.The evaluation is graded into four levels: Excellent, Good, Fair, Poor.

    Time frame: Immediately after procedure

  4. Tricuspid Regurgitation (TR) grade reduction

    Comparison of number of participants with reduction in TR between between experimental and active comparator arm.TR severity will be assessed using the 5-grade scale with the addition of "none/trace" to represent the lack of TR (scale: none/trace, mild, moderate, severe, massive, torrential). Lower grades of TR are better.

    Time frame: 30 days, 6 months, 12 months

  5. Change in KCCQ from baseline

    Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline.KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better health status.

    Time frame: 30 days, 6 months, 12 months

  6. Reduction in New York Heart Association (NYHA) functional class

    Total number of patients with NYHA functional class improvement of at least 1 class.NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

    Time frame: 30 days, 6 months, 12 months

  7. Change in 6MWD from baseline

    Change in 6MWD from baseline

    Time frame: 30 days, 6 months, 12 months

  8. Change in Quality of Life (QOL)

    Comparison of percentage of patients with improvement in any one of the three indicators - KCCQ score, NYHA functional class, or 6-minute walk test distance between experimental and active comparator arm. KCCQ overall summary score is a patient-reported measure of health status, ranging from 0 to 100, where higher scores reflect better health status.NYHA functional classification system categorizes heart failure patients into 4 classes based on physical activity limitation and symptom severity: class I (no symptoms and no limitation in ordinary physical activity), class II (mild symptoms and slight limitation during ordinary activity), class III (marked limitation in activity due to symptoms, even during less-than-ordinary activity; comfortable only at rest, and class IV (severe limitations; experiences symptoms even while at rest).

    Time frame: 30 days, 6 months, 12 months

  9. Heart failure hospitalizations

    Total number of patients with at least one hospital admission due to heart failure

    Time frame: 30 days, 6 months, 12 months

  10. Edema grade

    4-level assessment of edema severity

    Time frame: 30 days, 6 months, 12 months

  11. All-Cause Mortality

    Total number of deaths from any cause

    Time frame: 30 days, 6 months, 12 months

  12. Tricuspid valve re-intervention (percutaneous or surgical)

    Total number of patients with at least one non-elective tricuspid valve re-intervention

    Time frame: 30 days, 6 months, 12 months

  13. Rate of Major Adverse Events (MAE)

    Rate of Major Adverse Events (MAE) in treatment arm(TruGamma System in conjunction with OMT)

    Time frame: 6 months, 12 months

07

Study locations

1 of 1 sites recruiting
  • Cardiovascular Institute & Fuwai Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100037, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2028, 29 months after the start.

Of 86 interventional studies with no phase under Tricuspid Valve Insufficiency, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jul 8, 2026
StartActual
Mar 18, 2026
Primary completionEst.
Aug 30, 2028
CompletionEst.
Aug 30, 2028
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07691307
Lead sponsor
Jiangsu Trulive Medical Co., Ltd
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Mar 18, 2026
Primary completion
Aug 30, 2028 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Jul 8, 2026

Study contacts

Yuxiao Guo
Contact
kate.g@trulive.cn
+86 18221025921

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion